Letters Incretins and pancreatic cancer

Involving patients in drug licensing decisions

BMJ 2013; 347 doi: https://doi.org/10.1136/bmj.f4329 (Published 16 July 2013) Cite this as: BMJ 2013;347:f4329
  1. Nicky Britten, professor of applied health care research1,
  2. Sarah Denford, associate research fellow1,
  3. Ken Stein, director of peninsula technology assessment group (PenTAG)1
  1. 1University of Exeter Medical School, Institute of Health Research, Exeter EX2 4SG, UK
  1. N.Britten{at}exeter.ac.uk

Gale’s editorial about the adverse consequences of incretins concludes that: “The problem lies in a system that subordinates the public interest to commercial secrecy.”1 Another problem is that the system does not regard patients, or the public, as legitimate stakeholders whose judgments could or should contribute to licensing decisions.

The National Institute for Health Research Collaboration for Leadership in Applied Health Care …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe